Molecular Genetics of Drug-resistance in Epilepsies

Authors

  • Kurupath Radhakrishnan Professor & Head and Director, Department of Neurology,Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram-695011, Kerala.

Keywords:

genetics of epilepsy, AED-resistance,

Abstract

Nearly one-third of newly diagnosed patients with epilepsy remain unresponsive to antiepileptic drugs (AEDs), etiopathogenesis of which is poorly understood. The genes encoding the proteins that regulate the pharmacokinetics such as P-glycoprotein [ABCBI], major vault protein [MVP gene] and drug metabolizing enzymes [ABCB1, ABCG2, MVP, CYP2C9, CYP2C19, CYP3A4, CYP3A5, EPHX1, UGT1A1, UGT2B7], and pharmacodynamics such as sodium channels [SCN1A, SCN2A] and GABA receptors [GABRA1, GABRA6, GABRB2, GABRG2] of AEDs are under intense investigation to unravel the mysteries of AED-resistance. However, till today, a consistent and reliable result that could help the clinician either to predict drug resistance or to overcome it has not been forthcoming. The discrepant results may be related to variations in the definition of drug-resistance, heterogeneous patient populations, ethnic variations in the frequency distribution of single nucleotide polymorphisms (SNPs) and the selection of SNPs. Understanding of these limitations of existing studies, hopefully, will help in designing better studies. Nearly one-third of newly diagnosed patients with epilepsy remain unresponsive toantiepileptic drugs (AEDs), etiopathogenesis of which is poorly understood. The genesencoding the proteins that regulate the pharmacokinetics such as P-glycoprotein[ABCBI], major vault protein [MVP gene] and drug metabolizing enzymes [ABCB1,ABCG2, MVP, CYP2C9, CYP2C19, CYP3A4, CYP3A5, EPHX1, UGT1A1, UGT2B7],and pharmacodynamics such as sodium channels [SCN1A, SCN2A] and GABAreceptors [GABRA1, GABRA6, GABRB2, GABRG2] of AEDs are under intenseinvestigation to unravel the mysteries of AED-resistance. However, till today, aconsistent and reliable result that could help the clinician either to predict drugresistanceor to overcome it has not been forthcoming. The discrepant results may berelated to variations in the definition of drug-resistance, heterogeneous patientpopulations, ethnic variations in the frequency distribution of single nucleotidepolymorphisms (SNPs) and the selection of SNPs. Understanding of these limitationsof existing studies, hopefully, will help in designing better studies.Correspondence

Nearly one-third of newly diagnosed patients with epilepsy remain unresponsive to antiepileptic drugs (AEDs), etiopathogenesis of which is poorly understood. The genes encoding the proteins that regulate the pharmacokinetics such as P-glycoprotein [ABCBI], major vault protein [MVP gene] and drug metabolizing enzymes [ABCB1, ABCG2, MVP, CYP2C9, CYP2C19, CYP3A4, CYP3A5, EPHX1, UGT1A1, UGT2B7], and pharmacodynamics such as sodium channels [SCN1A, SCN2A] and GABA receptors [GABRA1, GABRA6, GABRB2, GABRG2] of AEDs are under intense investigation to unravel the mysteries of AED-resistance. However, till today, a consistent and reliable result that could help the clinician either to predict drug resistance or to overcome it has not been forthcoming. The discrepant results may be related to variations in the definition of drug-resistance, heterogeneous patient populations, ethnic variations in the frequency distribution of single nucleotide polymorphisms (SNPs) and the selection of SNPs. Understanding of these limitations of existing studies, hopefully, will help in designing better studies. Nearly one-third of newly diagnosed patients with epilepsy remain unresponsive toantiepileptic drugs (AEDs), etiopathogenesis of which is poorly understood. The genesencoding the proteins that regulate the pharmacokinetics such as P-glycoprotein[ABCBI], major vault protein [MVP gene] and drug metabolizing enzymes [ABCB1,ABCG2, MVP, CYP2C9, CYP2C19, CYP3A4, CYP3A5, EPHX1, UGT1A1, UGT2B7],and pharmacodynamics such as sodium channels [SCN1A, SCN2A] and GABAreceptors [GABRA1, GABRA6, GABRB2, GABRG2] of AEDs are under intenseinvestigation to unravel the mysteries of AED-resistance. However, till today, aconsistent and reliable result that could help the clinician either to predict drugresistanceor to overcome it has not been forthcoming. The discrepant results may berelated to variations in the definition of drug-resistance, heterogeneous patientpopulations, ethnic variations in the frequency distribution of single nucleotidepolymorphisms (SNPs) and the selection of SNPs. Understanding of these limitationsof existing studies, hopefully, will help in designing better studies.Correspondence

References

World Health Organization (2005). Atlas. Epilepsy Care in the World. Geneva: WHO Press, 20-24.

Sander JW, Shorvon SD (1996). Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 61: 433-443.

Kwan P, Brodie MJ (2000). Early identification of refractory epilepsy. N Engl J Med 342:314–319.

Radhakrishnan K (2009). Challenges in the management of epilepsy in resource-poor countries. Nat Rev Neurol 5: 323-330.

Kwan P, Arzimanoglou A, Berg AT, et al. (2010). Definition of drug resistantepilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.Epilepsia51:1069-1077.

Torta R, Keller R (1999). Behavioral, psychotic, and anxiety disorders in epilepsy: etiology, clinical features, and therapeutic implications. Epilepsia 40 (Suppl 10):S2-20.

Sperling MR, Feldman H, Kinman J, Liporace JD, O'Connor MJ (1999). Seizure control and mortality in epilepsy. Ann Neurol 46: 45–50.

Varma NP, Sylaja PN, George L, Sarma PS, Radhakrishnan K (2007). Employment concerns of people with epilepsy in Kerala, south India. Epilepsy Behav 10:250-254.

Santosh D, Kumar TS, Sarma PS, Radhakrishnan K (2007). Women with Onset of Epilepsy Prior to Marriage: Disclose or Conceal? Epilepsia 48:1007-1010.

Begley CE, Famulari M, Annegers JF, et al. (2000). The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 41: 342–351.

Regesta G, Tanganelli P (1999). Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34: 109-122.

Johnson MR, Tan NC, Kwan P, Brodie MJ (2011). Newly diagnosed epilepsy and pharmacogenomics research: A step in the right direction? Epilepsy Behav 22: 3-8.

Schmidt D, Löscher W (2005). Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46: 858-877.

Löscher W, Potschka, H (2005). Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76: 22-76.

Aronica E, Sisodiya S, Gorter J (2012). Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev 64: 919-929.

Remy S, Beck H (2006). Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain 129: 18-35.

Siddiqui A, Kerb R, Weale ME et al. (2003). Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.N Engl J Med 348: 1442-1448.

Das A, Balan S, Mathew A, Radhakrishnan VV, Banerjee M, Radhakrishnan K (2011). Corpora amylacea in the hippocampus of patients with mesial temporal lobe epilepsy: A new role for an old gene. Ind J Hum Genet 17 (Suppl. 1): S41-S47.

Cavanagh JB (1999). Corpora amylacea and the family of poyglycosan diseases. Brain Res Rev. 29: 265-295.

Das A, Balan S, Banerjee M, Radhakrishnan (2011). Drug resistance in epilepsy and

ABCB1 gene: The clinical perspective. Ind J Hum Genet 17 (Suppl. 1): S12-S21.

Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y (2009). Polymorphism of the MDR1/ABCB1 C3435T drugâ€transporter and resistance to anticonvulsant drugs: A metaâ€analysis. Epilepsia 50: 898-903.

Haerian B, Roslan H, Raymond A et al. (2010). ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure 19: 339-346.

Kim DW, Lee SK, Chu K et al. (2009). Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 84:86-90.

Ieiri I (2011). Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 27: 85-105.

Mossink MH, van Zon A, Scheper RJ, Sonnerveld P, Wiemer AC (2003). Vaults: a ribonucleoproten particle involved in drug resistance? Oncogene 22: 7458-67.

Van Zon A, Mossink MH, Scheper RJ, Sonnerveld P, Wiemer EAC (2003). The vault complex. Cell Mol Life Sci 60: 1828-37.

van Vliert EA, Aronica E, Redeker S, Gorter JA (2004). Expression and celluar distribution of major valut protein: a putative marker for pharmacoresistance in a rat model for temporal lobe epilepsy. Epilepsia 45: 1506-16.

Sisodiya SM, Martinian L, Scheffer GL, et al. (2003) Major vault protein, a marker of drug resistance, is upregulated in refractory epilepsy. Epilepsia 44: 1388-96.

Balan S, Lekshmi S, Sathyan S, Vijai J, Banerjee M, Radhakrishnan K (2013). Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy and hippocampal sclerosis. Gene 526 : 449-453.

Tate SK, Depondt C, Sisodiya SM, et al. (2005). Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Natl Acad Sci USA 102: 5507-5512.

Lakhan R, Kumari R, Singh K, Kalita J, Misra UK, Mittal B (2011). Possible role of CYP2C9 and CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. Ind J Med Res 134: 295-301.

Grover S, Gourie-Devi M, Baghel R, et al. (2010) Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics 11, 927-941.

Kwan P, Poon WS, Ng HK, et al. (2008). Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet Genomics 18, 989-898.

Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K (2008). Association between SCN1A polymorphism and carbamazepineâ€resistant epilepsy. Br J Clin Pharmacol 66 : 304-307.

Balan S, Vellichirammal NN, Banerjee M, Radhakrishnan K (2012). Failure to find association between febrile seizures and SCN1A rs3812718 polymorphism in south Indian patients with mesial temporal lobe epilepsy and hippocampal sclerosis. Epilepsy Res 101:288-292.

Bethmann K, Fritschy JM, Brandt C, Löscher W (2008). Antiepileptic drug resistant rats differ from drug responsive rats in GABAA receptor subunit expression in a model of temporal lobe epilepsy. Neurobiol Dis 31:169-187.

Kumari R, Lakhan R, Kalita J, Misra U, Mittal B (2010). Association of alpha subunit of GABA< sub> A receptor subtype gene polymorphisms with epilepsy susceptibility and drug resistance in north Indian population. Seizure 19, 237-241.

Kinirons P, Cavalleri GL, Singh R. et al. (2006) A pharmacogenetic exploration of vigabatrin-induced visual field constriction. Epilepsy Res 70: 144-152.

Cavalleri GL, McCormack M, Alhusaini S, Chaila E, Delanty N (2011). Pharmacogenomics and epilepsy: the road ahead. Pharmacogenomics 12, 1429-1447.

Zhang Y, Wang J, Zhao LM, et al. (2011) Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients. Eur J Clin Pharmacol 67: 885-887.

Löscher W, Klotz U, Zimprich F, Schmidt D (2009). The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50: 1-23.

Cavalleri GL, Weale ME, Shianna KV, et al. (2007). Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol 6: 970-980.

Cardon LR, Palmer LJ (2003). Population stratification and spurious allelic association. Lancet 361: 598-604.

Daly AK (2010). Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11: 241-246.

Published

2015-06-15

Issue

Section

ARTICLES